what to expect taking semaglutide & Tirzepatide First Dose of Semaglutide: What

Semaglutide and cardiovascular risk reduction In 2020, the Ozempic formulation of semaglutide (0.5 mg or 1.0 mg weekly) was approved to reduce the risk of major adverse cardiovascular events (ie, CV death, nonfatal myocardial infarction, and nonfatal stroke) in patients with T2DM and established CVD (Supplemental Table S5, This approval was based on the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial, which showed a 2.3% absolute risk reduction in these events compared with placebo, with most of the benefit obtained by reducing nonfatal stroke

GLP-1 , ,

(Fibroblast Growth Factor) may improve memory (19)

Be sure to let your healthcare provider know about all medications you take, including over-the-counter products